WO2011059263A3 - 뇌혈관 장벽을 통과하여 퇴행성 뇌신경 질환 부위의 세포사멸을 표적하는 펩타이드 및 이의 용도 - Google Patents

뇌혈관 장벽을 통과하여 퇴행성 뇌신경 질환 부위의 세포사멸을 표적하는 펩타이드 및 이의 용도 Download PDF

Info

Publication number
WO2011059263A3
WO2011059263A3 PCT/KR2010/008000 KR2010008000W WO2011059263A3 WO 2011059263 A3 WO2011059263 A3 WO 2011059263A3 KR 2010008000 W KR2010008000 W KR 2010008000W WO 2011059263 A3 WO2011059263 A3 WO 2011059263A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
brain
neurodegenerative
blood
composition
Prior art date
Application number
PCT/KR2010/008000
Other languages
English (en)
French (fr)
Other versions
WO2011059263A2 (ko
Inventor
이병헌
김인산
배재성
진희경
한형수
Original Assignee
경북대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 경북대학교 산학협력단 filed Critical 경북대학교 산학협력단
Publication of WO2011059263A2 publication Critical patent/WO2011059263A2/ko
Publication of WO2011059263A3 publication Critical patent/WO2011059263A3/ko
Priority to US13/469,729 priority Critical patent/US8900551B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

뇌혈관 장벽을 통과하여 퇴행성 뇌 질환 부위의 세포사멸을 표적하는 펩타이드 및 이의 용도에 관한 것으로, 보다 상세하게는 서열번호 1로 표시되는 아미노산 서열을 가지는 펩타이드를 유효성분으로 포함하는 뇌 조직으로의 약물전달용 조성물, 퇴행성 뇌신경 질환 부위의 사멸 세포(apoptotic cell) 검출용 조성물 및 퇴행성 뇌신경질환 부위의 영상화용 조성물 및 상기 펩타이드 및 이와 결합된 퇴행성 뇌신경 질환 예방/치료 및 치료진단용 조성물에 관한 것이다. 본 발명의 서열번호1로 표시되는 아미노산 서열을 가지는 펩타이드는 뇌혈관 장벽을 통과할 수 있으며, 퇴행성 뇌신경질환 조직 내 사멸세포와 특이적으로 결합할 수 있다. 따라서, 본 발명의 펩타이드는 퇴행성 뇌신경질환에서 아포토시스의 검출, 더 나아가 퇴행성 뇌신경질환 조직 내 사멸세포 (특히, 사멸신경세포)의 검출과 영상진단, 표적 약물전달, 치료진단 등의 목적으로 다양하게 사용될 수 있다.
PCT/KR2010/008000 2009-11-13 2010-11-12 뇌혈관 장벽을 통과하여 퇴행성 뇌신경 질환 부위의 세포사멸을 표적하는 펩타이드 및 이의 용도 WO2011059263A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/469,729 US8900551B2 (en) 2009-11-13 2012-05-11 Peptide which passes through blood-brain barrier and targets apoptosis of neurodegenerative brain disease site and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090109946A KR101077618B1 (ko) 2009-11-13 2009-11-13 뇌혈관 장벽을 통과하여 퇴행성 뇌신경 질환 부위의 세포사멸을 표적하는 펩타이드 및 이의 용도
KR10-2009-0109946 2009-11-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/469,729 Continuation US8900551B2 (en) 2009-11-13 2012-05-11 Peptide which passes through blood-brain barrier and targets apoptosis of neurodegenerative brain disease site and uses thereof

Publications (2)

Publication Number Publication Date
WO2011059263A2 WO2011059263A2 (ko) 2011-05-19
WO2011059263A3 true WO2011059263A3 (ko) 2011-11-10

Family

ID=43992238

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/008000 WO2011059263A2 (ko) 2009-11-13 2010-11-12 뇌혈관 장벽을 통과하여 퇴행성 뇌신경 질환 부위의 세포사멸을 표적하는 펩타이드 및 이의 용도

Country Status (3)

Country Link
US (1) US8900551B2 (ko)
KR (1) KR101077618B1 (ko)
WO (1) WO2011059263A2 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523330A (ja) 2000-02-04 2003-08-05 チルドレンズ・ホスピタル・リサーチ・ファウンデイション アテローム性動脈硬化症および関連疾患のための脂質加水分解治療
EP3205351B1 (en) 2010-04-23 2023-04-12 Alexion Pharmaceuticals, Inc. Lysosomal storage disease enzyme
NZ700824A (en) 2010-09-09 2016-03-31 Synageva Biopharma Corp Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
EP2675472A4 (en) 2011-02-15 2014-09-17 Synageva Biopharma Corp METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
KR20160068345A (ko) 2014-12-05 2016-06-15 경북대학교 산학협력단 사멸세포와 특이적으로 결합하는 고리형 펩타이드 및 이의 용도
WO2018102762A1 (en) * 2016-12-02 2018-06-07 Avelas Biosciences, Inc. Nerve labeling compositions and uses thereof
KR102385161B1 (ko) 2017-03-31 2022-04-08 도레이첨단소재 주식회사 복합편광필름, 이의 제조방법, 이를 포함하는 광원 어셈블리 및 액정표시장치
KR102087652B1 (ko) 2018-03-27 2020-03-11 한림대학교 산학협력단 동물의 혈관계의 시각화 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040071812A (ko) * 2003-02-07 2004-08-16 한국생명공학연구원 ＨＢｘ 단백질을 발현하는 간세포의 완전한 세포사멸을유도시키는 방법 및 이 방법을 이용하여 세포사멸 억제물질 및 유전자를 탐색하는 방법
US20050101524A1 (en) * 2001-11-08 2005-05-12 Hogg Philip J. Selective targeting of apoptotic cells
US20060046271A1 (en) * 2004-09-02 2006-03-02 Vanderbilt University Assessment of cancer susceptibility to molecular targeted therapy by use of recombinant peptides
KR20080093741A (ko) * 2007-04-18 2008-10-22 고려대학교 산학협력단 신경조직에서 사멸하는 신경세포의 확인 방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009139570A1 (en) 2008-05-14 2009-11-19 Kyungpook National University Industry-Academic Cooperation Foundation Peptides for targeting apoptotic cells and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101524A1 (en) * 2001-11-08 2005-05-12 Hogg Philip J. Selective targeting of apoptotic cells
KR20040071812A (ko) * 2003-02-07 2004-08-16 한국생명공학연구원 ＨＢｘ 단백질을 발현하는 간세포의 완전한 세포사멸을유도시키는 방법 및 이 방법을 이용하여 세포사멸 억제물질 및 유전자를 탐색하는 방법
US20060046271A1 (en) * 2004-09-02 2006-03-02 Vanderbilt University Assessment of cancer susceptibility to molecular targeted therapy by use of recombinant peptides
KR20080093741A (ko) * 2007-04-18 2008-10-22 고려대학교 산학협력단 신경조직에서 사멸하는 신경세포의 확인 방법

Also Published As

Publication number Publication date
US8900551B2 (en) 2014-12-02
KR101077618B1 (ko) 2011-10-27
US20120288447A1 (en) 2012-11-15
KR20110053119A (ko) 2011-05-19
WO2011059263A2 (ko) 2011-05-19

Similar Documents

Publication Publication Date Title
WO2011059263A3 (ko) 뇌혈관 장벽을 통과하여 퇴행성 뇌신경 질환 부위의 세포사멸을 표적하는 펩타이드 및 이의 용도
KR101922409B1 (ko) 화합물들 및 그 용도
WO2012142320A3 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
JP2011526886A5 (ko)
WO2010057112A3 (en) Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets
MX2012012225A (es) Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
IN2015DN04175A (ko)
TW200630327A (en) Substituted phenylalkanoic acids
WO2009075859A3 (en) Formulation of insulinotropic peptide conjugates
KR101853254B1 (ko) 펩타이드 및 그의 용도
WO2010065950A3 (en) Albumin binding peptide-mediated disease targeting
WO2007134245A3 (en) Elastin-like polymer delivery vehicles
WO2008050101A3 (en) Benzoyl amino heterocyclyl compounds useful in the treatment of a disease mediated through glk
JP2012501973A5 (ko)
WO2011052888A3 (ko) (3-플루오로-2-히드록시)프로필 작용기가 도입된 아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
WO2014153160A3 (en) METHOD OF ENHANCING THE BIODISTRIBUTION AND TISSUE TARGETING PROPERTIES OF THERAPEUTIC CeO2 PARTICLES VIA NANO-ENCAPSULATION AND COATING
WO2011149964A3 (en) Methods for treating or preventing vascular graft failure
EP4285994A3 (en) Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
WO2012012600A3 (en) Peptide compounds for regulating the complement system
EP2510941A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
JP2011528334A5 (ko)
Sang et al. Identification and target-modifications of temporin-PE: A novel antimicrobial peptide in the defensive skin secretions of the edible frog, Pelophylax kl. esculentus
CA2634902A1 (en) Anticancer agent comprising a peptide
WO2007145589A8 (en) Peptides that are capable of binding to amyloid-beta peptide.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10830195

Country of ref document: EP

Kind code of ref document: A2